Cobalt monatomic nano-enzyme ternary composite system as well as preparation method and application thereof

By using a ternary complex system of cobalt single-atom nanozyme, ginsenoside Rb1 and bifidobacteria, the multidimensional pathological challenges in the acute and chronic phases of UC treatment were addressed, achieving systemic regulation of inflammation and repair of the intestinal barrier, and providing multidimensional and long-term therapeutic effects.

CN121668334APending Publication Date: 2026-03-17CHANGCHUN UNIV OF CHINESE MEDICINE
0 Cites 2 Cited by

Patent Information

Application Number
CN202511995980.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2025-12-26
Publication Date
2026-03-17

AI Technical Summary

Technical Problem

Existing UC treatments are unable to simultaneously control acute inflammation and maintain chronicity, cannot systematically regulate inflammation and repair the intestinal barrier, and suffer from insufficient stability and targeting.

Method used

A cobalt single-atom nanozyme ternary composite system BB@Rb1@Co SA was constructed, integrating cobalt single-atom nanozyme, ginsenoside Rb1 and Bifidobacterium. Co SA clears ROS, Rb1 inhibits inflammatory pathways, and BB repairs the barrier, achieving multi-dimensional and long-term intervention.

Benefits of technology

It significantly alleviates oxidative stress, promotes mucosal repair, rebuilds the intestinal barrier, regulates the gut microbiota, provides long-term anti-inflammatory effects, is suitable for complex intestinal environments, and enhances the targeting and effectiveness of treatment.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention provides a cobalt monatomic nano-enzyme system modified by phospholipid polyethylene glycol carboxyl. The cobalt monatomic nano-enzyme system comprises a cobalt monatomic nano-enzyme composite core and phospholipid polyethylene glycol carboxyl compounded on the surface of cobalt monatomic nano-enzyme, the cobalt monatomic nano-enzyme composite core comprises a cobalt monatomic nano-enzyme and ginsenoside loaded on the cobalt monatomic nano-enzyme. The invention also provides a bifidobacterium synergetic cobalt monatomic nano-enzyme system which is formed by combining cobalt monatomic nano-enzyme with ginsenoside Rb1 and further delivering the cobalt monatomic nano-enzyme and ginsenoside Rb1 through bifidobacterium bifidum for targeted therapy of enteritis. The combination of Co SA and Rb1 can enhance the anti-inflammatory efficacy by adjusting a key immune signal pathway, and bifidobacterium bifidum can ensure targeted delivery of microbiota and promote intestinal barrier repair. The synergistic three-component strategy integrating monatomic nano-enzyme antioxidation, natural drug immunoregulation and probiotic targeting is provided, and a promising treatment platform is provided for accurate intervention of IBD.
Need to check novelty before this filing date? Find Prior Art